Paper Details

  1. Home
  2. Paper Details

Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.

Author: BandyopadhyaySanghamitra, ChatterjeeAbhijit, ChattopadhyayNaibedya, ChattopadhyaySourav, DasNabanita, DastidarKrishnarup Ghosh, DubeyShikha, GayenJiaur Rahaman, GurjarAnagha, JainMukul Rameshchandra, KumarHarish, KushwahaRajesh, KushwahaSapana, LataKiran, MohammedRiyazuddin, MohapatraJogeswar, PatelDinesh, RamachandranRavishankar, SanyalSabyasachi, ShreeSonal, SinghAbhishek Kumar, TripathiAnil Kumar, TrivediArun Kumar, VishwakarmaAchchhe Lal, YadavNamrata

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study identifies clofazimine, a leprosy drug, as a potential treatment for chronic myeloid leukemia (CML). Clofazimine induced apoptosis of blood mononuclear cells from CML patients, particularly in imatinib-resistant cells. Combining clofazimine with imatinib showed synergistic efficacy in a K562 xenograft study. Clinical evaluation of clofazimine in imatinib-refractory CML is suggested.
Paper Details　
Original Abstract of the Article :
Leukemia stem cells contribute to drug-resistance and relapse in chronic myeloid leukemia (CML) and BCR-ABL1 inhibitor monotherapy fails to eliminate these cells, thereby necessitating alternate therapeutic strategies for patients CML. The peroxisome proliferator-activated receptor-γ (PPAR&#947...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109729/

データ提供：米国国立医学図書館（NLM）

Harnessing the Power of Clofazimine for Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML) is a formidable foe, often defying traditional treatments. This study delves into the potential of clofazimine, a drug commonly used for leprosy, as a powerful weapon against CML. The research explores how clofazimine interacts with the PPARγ pathway, a key regulator of cell growth and survival, to effectively combat leukemia stem cells, the root cause of drug resistance. This study explores the synergistic effect of combining clofazimine with imatinib, a standard CML treatment, offering a promising new approach to combatting this challenging disease.

A New Frontier in CML Treatment: A Oasis in the Desert of Drug Resistance

This study provides a glimpse into a potential new oasis in the desert of CML treatment. The findings suggest that clofazimine, in combination with imatinib, could effectively target leukemia stem cells and improve treatment outcomes for patients with CML. This research holds promise for a more effective and durable treatment strategy for this challenging disease.

The Importance of Drug Re-purposing: A Journey Through the Desert of New Discoveries

This study highlights the importance of drug repurposing, a valuable approach to discovering new treatments. By exploring the potential of existing drugs for new applications, we can unlock a treasure trove of therapeutic possibilities. This research underscores the value of creative thinking and continued exploration in the search for innovative treatments.

Dr. Camel's Conclusion

The desert of drug discovery is a vast and ever-evolving landscape. This study underscores the power of repurposing existing drugs for new applications, offering hope for patients with CML. By harnessing the potential of clofazimine, we may be able to overcome the challenges of drug resistance and pave the way for a more effective treatment strategy.

Date :
  1. Date Completed 2021-04-27
  2. Date Revised 2021-04-27
Further Info :

Pubmed ID

31371410

DOI: Digital Object Identifier

PMC7109729

Related Literature

Article Analysis
・Side Effects of pioglitazone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.